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The purpose of this study was to evaluate the response of actively growing renal masses to stereotactic
body radiation therapy (SBRT). We retrospectively reviewed our institutional review boardeapproved
kidney database and identiﬁed 4 patients who underwent SBRT, 15 Gy dose, for their rapidly growing
renal masses. Three patients had a decreased tumor size after radiation treatment by 20.8%, 38.1%, and
20%. The other patient had a size gain of 5.6%. This patient maintained a similar tumor growth rate before
and after SBRT. Mean follow-up time was 13.8 months. SBRT represents an effective management option
in select patients with larger rapidly growing kidney masses.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
The detection of small renal masses has increased with the
frequency of cross-sectional imaging. Recent data suggest that
conservative management may be an attractive option for patients
who are poor surgical candidates with small renal masses.1 Ste-
reotactic body radiation therapy (SBRT) represents a novel treat-
ment approach in the setting of renal cell carcinoma (RCC). We
retrospectively reviewed the outcomes of 4 patients with rapidly
growing renal masses treated with SBRT who were medically unﬁt
for surgical intervention.Methods
We retrospectively reviewed our prospectively maintained
institutional review boardeapproved kidney database for all pa-
tients seen for a renal mass from 1994 to 2012. We identiﬁed 4
patients who were found to have rapidly growing renal masses and
were treated with SBRT as primary management. We examined
patient factors including age at diagnosis, time from diagnosis to
initial visit, tumor size, tumor growth rate, treatment dose, timeBY-NC-ND license (http://
he ethical standards of the
stitutional and national) and
08.
þ1 716-845-8773.
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Published by Elsevier Inc. All righfrom presentation to treatment, response to therapy, and patient-
reported toxicity as well as serum creatinine. Tumor size was
measured using the largest transverse dimension on computed
tomography (CT) scan.Simulation, Planning, and Treatment
All patients provided informed consent for SBRT. A
stereotactic body immobilization system (BodyFIX, Medical In-
telligence, Schwabmuenchen, Germany) was used in all cases.
Four-dimensional CT was obtained to assess tumor motion with
respiration. Target delineation was carried out in all respiratory
phases, creating an internal target volume by contouring gross
disease. A 5-mm isotropic expansion was used to create a plan-
ning target volume (PTV). Organs at risk segmented for evalua-
tion included kidney minus gross tumor volume, spinal cord,
liver, bowel, and stomach. Standard dose constraints were
applied for organs at risk.
Eclipse treatment planning software (Varian, Palo Alto, CA) was
used for radiation plan development. Inhomogeneity corrections
were applied. Guidelines for plan review were akin to that of the
contemporaneous RTOG 0915 protocol. Maximum dose was to be
located within the PTV. Conformality indices (ie, dose spillage)
consistent with the previously mentioned protocol were in
compliance.
A 15 Gy dose was prescribed to the PTV. Treatment was carried
out with Varian Trilogy linear accelerator. Volumetric modulated
arc therapy with 6 MeV photons was used. Cone-beam CT was
obtained following setup, and appropriate shifts were made.ts reserved.
Table 1
Tumor response
Patient 1 Patient 2 Patient 3 Patient 4 Mean
Age at diagnosis, y 89 72 73 70 76
Tumor size at diagnosis, cm 4.1 4.0 3.5 3.6 3.8
Time from diagnosis to initial visit, mo 14.6 0.9 23.7 32.4 17.9
Tumor size at initial visit, cm 5.1 4.8 4.2 4.0 4.53
Tumor growth rate from diagnosis to initial visit, cm/y 0.69 10.67 0.36 0.14 3.0
Approx tumor size at time of treatment, cm 5.4 4.8 4.2 6.0 5.1
SBRT treatment dose, Gy 15 15 15 15 15
Time from visit to treatment completion, mo 2.17 5.83 2.5 17.8 7.07
Tumor size at last follow-up, cm 5.7 3.8 2.7 4.8 4.25
Size reduction (%) 5.56 20.8 38.1 20 18.3
Overall size reduction, cm 0.3 1 1.6 1.2 0.85
Follow-up, mo 6 22 21 6 13.8
SBRT, stereotactic body radiation therapy.
M. Hanzly et al. / Urology Case Reports 2 (2014) 147e149148Results
Three of 4 patients had a measurable decrease in size of their
renal mass. The average change was 0.85 cm decrease in size afterFigure 1. Pretreatment and Ptreatment (P ¼ .06). Average follow-up was 13.8 months, which
included cross-sectional imaging at the last recorded visit. The
mean age at diagnosis was 76 years with a mean tumor size of
3.8 cm (Table 1).ost-treatment imaging.
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have a successful response to SBRT therapy. The patient was diag-
nosedwith a 4.1-cm lower pole tumor. He re-presented 14.6months
later after the tumor grew to 5.1 cm (Fig.1), a growth rate of 0.69 cm/
y. He underwent treatment with a maximal tumor size of 5.4 cm. At
6-month follow-up, the tumor had grown to 5.7 cm (Fig. 1), an
increase of 0.3 cm (5.6%). This tumor failed to respond to SBRT and
continued to progress with an increase in the rate of growth to
0.74 cm/y.
The second patient, a 72-year-old African-American man, had a
successful response to therapy. The patient was diagnosed with a
4-cm upper lobe tumor that grew to 4.8 cm (Fig. 1) in 1 month,
giving a growth rate of 10.67 cm/y. The patient’s most recent
follow-up was 22 months after treatment and revealed a 3.8-cm
tumor (Fig. 1), a 20.8% reduction.
The third patient, a 73-year-old Caucasian male, had a successful
response to therapy. The patient was diagnosed with a 3.5-cm mid
to upper pole right renal mass that grew to 4.2 cm (Fig. 1) in
23.7 months, demonstrating a growth rate of 0.36 cm/y. Follow-up
CT 21 months after treatment revealed a 2.7-cm tumor (Fig. 1), a
38.1% reduction.
The fourth patient, a 70-year-old Caucasian man, also had a
successful response to therapy. The patient was diagnosed with
a 3.6-cm tumor. During surveillance, the tumor grew to 6.0 cmwith
a growth rate calculated 3.0 cm/y. At 6months follow-up, the tumor
decreased in size to 4.8 cm (Fig. 1), a 20% reduction.
In all 4 patients, there was no signiﬁcant decline in serum
creatinine from prior baseline levels after SBRT at most recent
follow-up. No adverse events were reported.
Discussion
The limitations of our data are well recognized. Among these are
small sample size, inconsistent follow-up, and lack of histologic
veriﬁcation. Given the lack of a tissue diagnosis in our patients, we
chose the conservative dose of 15 Gy in one fraction. Besides the
high likelihood of sparing organs at risk, there were data to suggest
that a threshold exists around 15 Gy for increased cell kill because
of effects on endothelial cells.2
There is now an actively growing body of literature for the
use of SBRT in RCC. The preliminary results of one of the largestexperiences to date revealed 93% local control in patients after a
mean 12-month follow-up, using 40 Gy in 5 fractions.3 Ponksy et al4
reported that 16 Gy in 4 fractions achieved a pathologic complete
response in only 1 of 3 patients with nephrectomy 8 weeks after
radiation. Nevertheless, a modest size reduction was seen in our
patients after SBRT treatment. Toxicity rates were low in these se-
ries, which was consistent with our results.
The increasing acceptance of SBRT in other disease sites coupled
with the common notion that RCC is a radioresistant histology
renders SBRT an attractive treatment option in inoperable patients.
Our series suggests that SBRT is a safe and feasible treatment option
for this patient population. Even with a modest dose of 15 Gy,
response was seen in 3 of 4 patients.Conclusion
SBRT decreases the size of rapidly growing renal masses with
even modest doses, and may represent a viable treatment option in
the medically inoperable treatment population as it is safe and well
tolerated. Future prospective studies are needed with larger
numbers, standardized dosing, and histologic conﬁrmation.Consent
Informed consent was obtained from all patients for being
included in the study.
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